$PTCT
PTC Therapeutics Inc Stock $ptct

$ptct Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-Q Financial Statement

#000107008120000128 Filed on August 05, 2020

Income Statement

Concept	2020 Q3	2020 Q2	2019 Q2
Revenue	$118.4M	$75.24M	$85.52M
YoY Change	65.79%	-12.02%	24.41%
Cost Of Revenue	$4.700M	$5.300M	$3.211M
YoY Change	56.35%	65.06%	24.84%
Gross Profit	$113.7M	$69.90M	$82.31M
YoY Change	66.2%	-15.08%	24.39%
Gross Profit Margin	96.03%	92.9%	96.25%
Selling, General & Admin	$57.84M	$53.66M	$49.22M
YoY Change	17.36%	9.03%	46.71%
% of Gross Profit	50.87%	76.77%	59.79%
Research & Development	$93.00M	$176.5M	$59.98M
YoY Change	47.44%	194.31%	83.95%
% of Gross Profit	81.79%	252.54%	72.87%
Depreciation & Amortization	$11.64M	$10.21M	$7.700M
YoY Change	43.0%	32.6%	23.79%
% of Gross Profit	10.24%	14.61%	9.35%
Operating Expenses	$173.5M	$262.5M	$124.3M
YoY Change	31.57%	111.23%	67.23%
Operating Profit	-$55.13M	-$187.3M	-$38.76M
YoY Change	-8.84%	383.19%	595.34%
Interest Expense	-$21.04M	-$5.379M	-$2.074M
YoY Change	689.16%	159.35%	-28.09%
% of Operating Profit
Other Income/Expense, Net	$28.77M	$11.31M	-$183.0K
YoY Change	927.36%	-6279.78%	-72.81%
Pretax Income	-$47.40M	-$181.3M	-$41.02M
YoY Change	-21.44%	342.14%	349.18%
Income Tax	$22.29M	$84.00K	$774.0K
% Of Pretax Income
Net Earnings	-$69.69M	-$181.4M	-$41.79M
YoY Change	16.16%	334.15%	338.96%
Net Earnings / Revenue	-58.86%	-241.13%	-48.86%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.031M	-$2.782M	-$747.8K
COMMON SHARES
Basic Shares Outstanding	67.70M shares	62.88M shares	58.43M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q3	2020 Q2	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.141B	$498.9M	$363.5M
YoY Change	61.02%	37.25%	22.76%
Cash & Equivalents	$434.0M	$158.5M	$136.1M
Short-Term Investments	$707.0M	$340.4M	$227.4M
Other Short-Term Assets	$26.90M	$34.10M	$17.40M
YoY Change	29.95%	95.98%	176.19%
Inventory	$19.48M	$18.37M	$16.90M
Prepaid Expenses
Receivables	$56.80M	$53.60M	$77.10M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.244B	$605.0M	$475.0M
YoY Change	54.2%	27.38%	26.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$28.14M	$26.81M	$15.39M
YoY Change	52.25%	74.17%	87.31%
Goodwill	$82.30M	$82.30M	$82.30M
YoY Change	0.0%	0.0%
Intangibles	$712.5M	$708.8M	$702.7M
YoY Change	1.37%	0.87%	456.44%
Long-Term Investments
YoY Change
Other Assets	$28.10M	$48.80M	$5.800M
YoY Change	63.37%	741.38%	262.5%
Total Long-Term Assets	$936.9M	$871.6M	$816.6M
YoY Change	12.25%	6.74%	499.89%
TOTAL ASSETS
Total Short-Term Assets	$1.244B	$605.0M	$475.0M
Total Long-Term Assets	$936.9M	$871.6M	$816.6M
Total Assets	$2.181B	$1.477B	$1.292B
YoY Change	32.87%	14.33%	152.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$15.66M	$15.47M	$10.22M
YoY Change	74.83%	51.34%	134.17%
Accrued Expenses	$68.00M	$51.10M	$35.70M
YoY Change	34.12%	43.14%	174.62%
Deferred Revenue	$5.992M	$7.702M	$8.005M
YoY Change	-31.99%	-3.79%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$18.33M	$20.00M
YoY Change	-100.0%	-8.34%	1100.48%
Total Short-Term Liabilities	$253.8M	$201.8M	$174.0M
YoY Change	38.32%	16.03%	101.17%
LONG-TERM LIABILITIES
Long-Term Debt	$303.0M	$297.0M	$135.7M
YoY Change	3.35%	118.91%	-7.83%
Other Long-Term Liabilities	$1.968M	$26.68M	$8.416M
YoY Change	-79.19%	216.99%	5400.65%
Total Long-Term Liabilities	$304.9M	$323.7M	$144.1M
YoY Change	0.77%	124.64%	-2.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$253.8M	$201.8M	$174.0M
Total Long-Term Liabilities	$304.9M	$323.7M	$144.1M
Total Liabilities	$1.670B	$904.1M	$802.9M
YoY Change	70.8%	12.61%	228.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.555B	-$1.485B	-$1.053B
YoY Change	39.69%	41.03%	25.39%
Common Stock	$68.00K	$67.00K	$58.00K
YoY Change	11.48%	15.52%	23.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$511.0M	$572.5M	$488.7M
YoY Change
Total Liabilities & Shareholders Equity	$2.181B	$1.477B	$1.292B
YoY Change	32.87%	14.33%	152.37%

Cashflow Statement

Concept	2020 Q3	2020 Q2	2019 Q2
OPERATING ACTIVITIES
Net Income	-$69.69M	-$181.4M	-$41.79M
YoY Change	16.16%	334.15%	338.96%
Depreciation, Depletion And Amortization	$11.64M	$10.21M	$7.700M
YoY Change	43.0%	32.6%	23.79%
Cash From Operating Activities	$26.65M	-$74.81M	-$30.52M
YoY Change	-271.94%	145.12%
INVESTING ACTIVITIES
Capital Expenditures	-$3.310M	-$2.160M	-$1.980M
YoY Change	-22.12%	9.09%	178.87%
Acquisitions
YoY Change
Other Investing Activities	-$390.9M	$144.2M	-$36.19M
YoY Change	-1227.19%	-498.51%	-528.28%
Cash From Investing Activities	-$394.2M	$142.1M	-$38.17M
YoY Change	-1395.47%	-472.15%	-592.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	643.1M	-32.92M	2.850M
YoY Change	68.18%	-1255.09%	-97.66%
NET CHANGE
Cash From Operating Activities	26.65M	-74.81M	-30.52M
Cash From Investing Activities	-394.2M	142.1M	-38.17M
Cash From Financing Activities	643.1M	-32.92M	2.850M
Net Change In Cash	275.5M	34.32M	-65.84M
YoY Change	-30.66%	-152.13%	-150.89%
FREE CASH FLOW
Cash From Operating Activities	$26.65M	-$74.81M	-$30.52M
Capital Expenditures	-$3.310M	-$2.160M	-$1.980M
Free Cash Flow	$29.96M	-$72.65M	-$28.54M
YoY Change	-366.31%	154.56%	-4119.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001070081
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35969
	dei	Entity Registrant Name EntityRegistrantName	PTC Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3416587
	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Corporate Court
	dei	Entity Address City Or Town EntityAddressCityOrTown	South Plainfield,
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07080
	dei	City Area Code CityAreaCode	908
	dei	Local Phone Number LocalPhoneNumber	222-7000
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	PTCT
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	67703214	shares
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	158461000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	288028000	USD
CY2020Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	340430000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	398535000	USD
CY2020Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	53644000	USD
CY2019Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	55538000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	18373000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	19285000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	34116000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17898000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	605024000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	779284000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26806000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21549000	USD
CY2020Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	708814000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	710500000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	82341000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	82341000	USD
CY2020Q2	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	53652000	USD
CY2019Q4	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	30108000	USD
CY2020Q2	us-gaap	Assets Assets	1476637000	USD
CY2019Q4	us-gaap	Assets Assets	1623782000	USD
CY2020Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	164376000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	159276000	USD
CY2020Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	18333000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	20000000	USD
CY2020Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7702000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8242000	USD
CY2020Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	4180000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2020Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4868000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8339000	USD
CY2020Q2	ptct	Business Combination Consideration Liability Deferred Consideration Payable Current BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent	2384000	USD
CY2019Q4	ptct	Business Combination Consideration Liability Deferred Consideration Payable Current BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent	40000000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	201843000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	235857000	USD
CY2020Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3415000	USD
CY2020Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	297029000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	293859000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	225700000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	356300000	USD
CY2020Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	130862000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	130862000	USD
CY2020Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	22031000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	26678000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9159000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	904143000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	1029452000	USD
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67240679	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61935870	shares
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	67000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	62000	USD
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2067274000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1795351000	USD
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10016000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10584000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1484831000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1190499000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	572494000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	594330000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1476637000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1623782000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	75239000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	85522000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	143498000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	139105000	USD
CY2020Q2	ptct	Costof Goodsand Service Excluding Amortization Of Intangible Assets CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets	5304000	USD
CY2019Q2	ptct	Costof Goodsand Service Excluding Amortization Of Intangible Assets CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets	3211000	USD
	ptct	Costof Goodsand Service Excluding Amortization Of Intangible Assets CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets	9389000	USD
	ptct	Costof Goodsand Service Excluding Amortization Of Intangible Assets CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets	5587000	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8731000	USD
CY2019Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6575000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16679000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12652000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	176525000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	59979000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	266632000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	112544000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	53659000	USD
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	49215000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	111869000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	89760000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	-7680000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-11021000	USD
CY2019Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	-5300000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	-8580000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	-26460000	USD
CY2020Q2	ptct	Settlement Of Deferred And Contingent Consideration SettlementOfDeferredAndContingentConsideration	10613000	USD
CY2019Q2	ptct	Settlement Of Deferred And Contingent Consideration SettlementOfDeferredAndContingentConsideration	0	USD
	ptct	Settlement Of Deferred And Contingent Consideration SettlementOfDeferredAndContingentConsideration	10613000	USD
	ptct	Settlement Of Deferred And Contingent Consideration SettlementOfDeferredAndContingentConsideration	0	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	262512000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	124280000	USD
	us-gaap	Operating Expenses OperatingExpenses	423762000	USD
	us-gaap	Operating Expenses OperatingExpenses	247003000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-187273000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-38758000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-280264000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-107898000	USD
CY2020Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-5379000	USD
CY2019Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2074000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4362000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11309000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-183000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2523000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-292000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-181343000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-41015000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-293808000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-112552000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	84000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	774000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	306000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1350000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-181427000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-41789000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-294114000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-113902000	USD
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	65150780	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55912748	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	63769958	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57113141	shares
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.78
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.75
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.61
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.99
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-181427000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-41789000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-294114000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-113902000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2718000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	839000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2655000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	898000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-181427000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-10749000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	278000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2087000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-438000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-189458000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40672000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-293546000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-113442000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	528734000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5447000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	42869000	USD
CY2020Q2	ptct	Stock Issued During Period Value Exchange Rights StockIssuedDuringPeriodValueExchangeRights	150528000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15058000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2406000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16910000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-181427000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-8031000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	572494000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	512942000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	106000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2847000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1564000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10920000	USD
CY2019Q2	ptct	Adjustments To Additional Paid In Capital Receivable From Investor AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor	978000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-41789000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1117000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	488685000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	594330000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	18950000	USD
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	42869000	USD
	ptct	Stock Issued During Period Value Exchange Rights StockIssuedDuringPeriodValueExchangeRights	150528000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1600000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	129000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	25045000	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2406000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32130000	USD
	us-gaap	Stockholders Equity Period Increase Decrease StockholdersEquityPeriodIncreaseDecrease	-218000	USD
	us-gaap	Stockholders Equity Period Increase Decrease StockholdersEquityPeriodIncreaseDecrease	-218000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-294114000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	568000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	572494000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	350727000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	224545000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4129000	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1564000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20184000	USD
	ptct	Adjustments To Additional Paid In Capital Receivable From Investor AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor	978000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-113902000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	460000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	488685000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-294114000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-113902000	USD
	us-gaap	Depreciation Depreciation	19445000	USD
	us-gaap	Depreciation Depreciation	14760000	USD
	ptct	Operating Lease Cost Non Cash OperatingLeaseCostNonCash	2401000	USD
	ptct	Operating Lease Cost Non Cash OperatingLeaseCostNonCash	1256000	USD
	ptct	Finance Lease Cost Non Cash FinanceLeaseCostNonCash	41212000	USD
	ptct	Finance Lease Cost Non Cash FinanceLeaseCostNonCash	0	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	8580000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	26460000	USD
	ptct	Settlement Of Deferred And Contingent Consideration SettlementOfDeferredAndContingentConsideration	10613000	USD
	ptct	Settlement Of Deferred And Contingent Consideration SettlementOfDeferredAndContingentConsideration	0	USD
	ptct	Shares Issued Asset Acquisition SharesIssuedAssetAcquisition	42869000	USD
	ptct	Shares Issued Asset Acquisition SharesIssuedAssetAcquisition	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7250000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-1860000	USD
	ptct	Unrealized Gain Losson Convertible Securities UnrealizedGainLossonConvertibleSecurities	749000	USD
	ptct	Unrealized Gain Losson Convertible Securities UnrealizedGainLossonConvertibleSecurities	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	10993000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	4055000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-26000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-50000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	635000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	907000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	510000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	280000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	32130000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	20184000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	3248000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-62000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-943000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	852000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16569000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	9702000	USD
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	175000	USD
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	9656000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7497000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7546000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-4132000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	7395000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3925000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2511000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-156364000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-72931000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8183000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4851000	USD
	ptct	Payments To Acquire Convertible Debt Investment PaymentsToAcquireConvertibleDebtInvestment	10000000	USD
	ptct	Payments To Acquire Convertible Debt Investment PaymentsToAcquireConvertibleDebtInvestment	0	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	367102000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	226261000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	428490000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	58424000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2422000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	11981000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	4000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	40783000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-188669000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	25045000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4129000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18950000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	224545000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	10000000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	1667000	USD
	ptct	Payments On Deferred Consideration Obligation PaymentsOnDeferredConsiderationObligation	35829000	USD
	ptct	Payments On Deferred Consideration Obligation PaymentsOnDeferredConsiderationObligation	0	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2406000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1564000	USD
	ptct	Payment Of Finance Lease Principal PaymentOfFinanceLeasePrincipal	15000000	USD
	ptct	Payment Of Finance Lease Principal PaymentOfFinanceLeasePrincipal	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-14428000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	228571000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	442000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-375000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-129567000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-33404000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	295528000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	169498000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	165961000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	136094000	USD
	us-gaap	Interest Paid Net InterestPaidNet	5286000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3111000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1140000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1013000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2655000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	898000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	18117000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	11643000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	41212000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	12186000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	8269000	USD
	ptct	Stock Issued During Period Value Exchange Rights StockIssuedDuringPeriodValueExchangeRights	150528000	USD
	ptct	Stock Issued During Period Value Exchange Rights StockIssuedDuringPeriodValueExchangeRights	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	The Company<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">PTC Therapeutics, Inc. (the “Company” or “PTC”) is a science-driven global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The Company’s ability to globally commercialize products is the foundation that drives its continued investment in a robust diversified pipeline of transformative medicines and its mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company’s strategy is to bring best-in-class therapies with differentiated clinical benefit to patients affected by rare disorders and to leverage its global commercial infrastructure to maximize value for its patients and other stakeholders.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company has two products, Translarna</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">™ </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(ataluren) and Emflaza™ (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD, a rare, life threatening disorder. Translarna has marketing authorization in the European Economic Area (the “EEA”) for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients aged 2 years and older and in Brazil for the treatment of nmDMD in ambulatory patients aged 5 years and older, subject to annual renewal and other conditions. In June 2020, the Committee for Medicinal Products for Human Use (the "CHMP") of the European Medicines Agency ("EMA") recommended to remove the statement “efficacy has not been demonstrated in non-ambulatory patients” from the product label for Translarna. The CHMP's opinion is subject to final approval by the European Commission, which is typically provided within two months of the CHMP's recommendation. Emflaza is approved in the United States for the treatment of DMD in patients two years and older.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (“CNS”) including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase, or AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. The Company is preparing a biologics license application ("BLA") for PTC-AADC for the treatment of AADC deficiency in the United States and it anticipates initiating the BLA submission to the United States Food and Drug Administration ("FDA") in the second half of 2020. In January 2020, the Company submitted a marketing authorization application ("MAA") to the EMA for PTC-AADC for the treatment of AADC deficiency in the EEA, and the Company expects an opinion from the CHMP in the first quarter of 2021.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company holds the rights for the commercialization of Tegsedi™ (inotersen) and Waylivra™ (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to the Company’s Collaboration and License Agreement with Akcea Therapeutics, Inc. (“Akcea”). Tegsedi has received marketing authorization in the United States, the European Union (the “EU”) and Brazil for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis, or hATTR amyloidosis. Waylivra has received marketing authorization in the EU for the treatment of familial chylomicronemia syndrome, or FCS. The Company filed for marketing authorization for Waylivra for the treatment of FCS with ANVISA, the Brazilian health regulatory authority, in June 2020 and, subject to potential delays in the review process related to the COVID-19 pandemic, expects a regulatory decision on approval from ANVISA in 2021.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also has a spinal muscular atrophy ("SMA") collaboration with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., referred to collectively as Roche, and the Spinal Muscular Atrophy Foundation ("SMA Foundation"). The lead compound in the SMA program is risdiplam (RG7916, RO7034067). Roche submitted an NDA for risdiplam to the FDA in the fourth quarter of 2019. In April 2020, the FDA extended the Prescription Drug User Fee Act ("PDUFA") date for a decision from May 24, 2020 to August 24, 2020 as a result of additional data that Roche submitted, including comprehensive data from the Sunfish part 2 study. Risdiplam is expected to be indicated in the United States for SMA type 1, 2 and 3 patients, if approved. Roche anticipates submitting an MAA for risdiplam in the EEA imminently.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On October 25, 2019, the Company completed the acquisition of substantially all of the assets of BioElectron Technology Corporation (“BioElectron”), a Delaware corporation, including certain compounds that the Company has begun to develop as part of its Bio-e platform, (the “Asset Acquisition”) pursuant to an asset purchase agreement by and between the Company and BioElectron, dated October 1, 2019 (the “Asset Acquisition Agreement”). The transaction was accounted for as an asset acquisition. The two most advanced molecules in the Company's Bio-e platform are vatiquinone, formerly known as PTC743, and PTC857. The Company expects to initiate a potential registrational Phase 2 placebo-controlled trial of vatiquinone in approximately 60 children with mitochondrial disease and associated refractory epilepsy in the third quarter of 2020. The Company also expects to initiate a potential registrational Phase 3 trial of vatiquinone in approximately 100 patients with </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Friedrich ataxia in the fourth quarter of 2020. In the second quarter of 2020, the Company initiated a Phase 1 trial in healthy volunteers to evaluate the safety and pharmacology of PTC857. The Company expects data from the single ascending dose and multiple ascending dose studies from the Phase 1 trial to be available by the end of 2020.</span></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company’s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission following reassessment by the EMA of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. This marketing authorization is further subject to the specific obligation to conduct and submit the results of a multi-center, randomized, double-blind, 18-month, placebo-controlled trial, followed by an 18-month open-label extension, according to an agreed protocol, in order to confirm the efficacy and safety of Translarna. The final report on the trial and open-label extension is to be submitted by the Company to the EMA by the end of the third quarter of 2022. The Company refers to the trial and open-label extension together as Study 041.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The marketing authorization in the EEA was last renewed in June 2020 and is effective, unless extended, through August 5, 2021. The renewal was based on the Company’s commitment to conduct Study 041 and the totality of the clinical data available from its trials and studies of Translarna for the treatment of nmDMD, including the safety and efficacy results of the Phase 2b and Phase 3 clinical trials. The primary efficacy endpoint was not achieved in either trial within the pre-specified level of statistical significance.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Translarna is an investigational new drug in the United States. During the first quarter of 2017, the Company filed a New Drug Application, or NDA, over protest with the FDA, for which the FDA granted a standard review. In October 2017, the Office of Drug Evaluation I of the FDA issued a complete response letter for the NDA, stating that it was unable to approve the application in its current form. In response, the Company filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied the Company's appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients’ muscles. The Company intends to follow the FDA’s recommendation and will collect, using newer technologies via procedures and methods that the Company designed, such dystrophin data in a new study, Study 045, which the Company initiated in the fourth quarter of 2018. As a result of intermittent discontinuations of certain elective procedures at the Company's clinical trial site in response to the COVID-19 pandemic, the Company's expected completion of Study 45 has been delayed as certain patients still require final study muscle biopsies. Once the clinical trial site is open for the necessary procedures and patients are able to safely travel to the site, the Company expects to be able to complete the final biopsies and the data from Study 045 would be available thereafter, followed by a potential re-submission of an NDA. Additionally, should a re-submission of an NDA receive accelerated approval, the Office of New Drugs stated that Study 041, which is currently enrolling, could serve as the confirmatory post-approval trial required in connection with the accelerated approval framework.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc., or Agilis, pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the “Merger Agreement”), by and among the Company, Agility Merger Sub, Inc., a Delaware corporation and the Company's wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, (the "Merger").</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon the closing of the Merger, the Company paid to Agilis equityholders total upfront consideration comprised of $49.2 million in cash and 3,500,907 shares of the Company’s common stock (the “Closing Stock Consideration”). The Closing Stock Consideration was determined by dividing $150.0 million by the volume-weighted average price per share of the Company’s common stock on the Nasdaq Global Select Market for the 10 consecutive trading-day period ending on the second trading-day immediately preceding the closing of the Merger. Agilis equityholders are entitled to receive contingent payments from the Company based on the achievement of certain development, regulatory and net sales milestones as well as based upon a percentage of net sales of certain products.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On April 29, 2020, the Company, certain of the former equity holders of Agilis, and, for the limited purposes set forth in the agreement, Shareholder Representative Services LLC, entered into a Rights Exchange Agreement (the “Rights Exchange Agreement”). Pursuant to the Rights Exchange Agreement, the Company issued 2,821,176 shares of its common stock (the “Common Stock Consideration”) and paid $36.9 million (the “Cash Consideration”), in the aggregate, to such former equity holders of Agilis (the “Participating Rightholders”) in exchange for the cancellation and forfeiture by the Participating Rightholders of their rights to receive certain milestone-based contingent payments under the Merger Agreement, pursuant to which the Company completed the Merger. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Pursuant to the terms of the Rights Exchange Agreement, the Participating Rightholders have canceled and forfeited their rights under the Merger Agreement to receive (i) $174.0 million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6 million, in the aggregate, of $40.0 million in development milestone payments that would have been due upon the passing of the second anniversary of the closing of the Merger, regardless of whether the milestones are achieved.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Rights Exchange Agreement has no effect on the Merger Agreement other than to provide for the cancellation and forfeiture of the Participating Rightholders’ rights to receive $211.6 million, in the aggregate, of the milestone payments described above. As a result, all other rights and obligations under the Merger Agreement remain in effect pursuant to their terms, including the Company’s obligation to pay up to an aggregate maximum amount of $22.4 million upon the achievement of certain development milestones (representing the remaining portion of potential development milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement after deducting the $37.6 million for which rights were canceled and forfeited pursuant to the Rights Exchange Agreement from the $40.0 million in development milestone payments that are due upon the passing of the second anniversary of the closing of the Merger), up to an aggregate maximum amount of $361.0 million upon the achievement of certain regulatory milestones (representing the remaining portion of potential regulatory milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement), up to a maximum aggregate amount of $150.0 million upon the achievement of certain net sales milestones and a percentage of annual net sales for Friedreich ataxia and Angelman syndrome during specified terms, ranging from 2% to 6%, pursuant to the terms of the Merger Agreement. Refer to Note 5 for further details regarding the Rights Exchange Agreement.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On May 29, 2020, the Company completed its acquisition of Censa Pharmaceuticals, Inc., (“Censa”) pursuant to an Agreement and Plan of Merger, dated as of May 5, 2020, (the "Censa Merger Agreement"), by and among the Company, Hydro Merger Sub, Inc., the Company's wholly owned, indirect subsidiary, and, solely in its capacity as the representative, agent and attorney-in-fact of the securityholders of Censa, Shareholder Representative Services LLC (the "Censa Merger"). The transaction was accounted for as an asset acquisition. In connection with the Censa Merger, the Company acquired PTC923 (formerly known as CNSA-001), which is being pursued as a possible treatment for orphan metabolic diseases associated with defects in the tetrahydrobiopterin biochemical pathways, including phenylketonuria ("PKU"). Refer to Note 3 for further details.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020, the Company had an accumulated deficit of approximately $1,484.8 million. The Company has financed its operations to date primarily through the private offerings in September 2019 of 1.50% convertible senior notes due 2026 and in August 2015 of 3.00% convertible senior notes due 2022 (see Note 11), public offerings of common stock in February 2014, October 2014, April 2018, January 2019, and September 2019, "at the market offerings" of its common stock, its initial public offering of common stock in June 2013, private placements of its convertible preferred stock, collaborations, bank debt, the Company's credit and security agreement (the "Credit Agreement"), with MidCap Financial Trust, or MidCap Financial, as administrative agent and MidCap Financial and other certain institutions as lenders thereto (see Note 11), grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company’s product candidates. Since 2014, the Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States, and since May 2017, the Company has generated revenue from net sales of Emflaza for the treatment of DMD in the United States. The Company expects that cash flows from the sales of its products, together with the Company's cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months.</span></div>
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1484800000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of estimates</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, certain accruals related to the Company’s research and development expenses, valuation procedures for convertible notes, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div>
CY2020Q2	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	7500000	USD
	ptct	Termforletterofcredit Termforletterofcredit	P5Y
	ptct	Termforletterofcredit Termforletterofcredit	P5Y
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	288028000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	158461000	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	7500000	USD
CY2020Q2	us-gaap	Restricted Cash RestrictedCash	7500000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	295528000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	165961000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	877000	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	874000	USD
CY2020Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	8666000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	9652000	USD
CY2020Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8830000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8759000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	18373000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	19285000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	200000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2019Q2	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2020Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	200000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	300000	USD
CY2020Q2	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	0	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	0	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	122000000.0	USD
CY2020Q2	ptct	Number Of Operating Leases NumberOfOperatingLeases	3	operating_lease
CY2020Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P10Y
CY2020Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	2600000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	5000000.0	USD
CY2019Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	1100000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2100000	USD
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1970000	USD
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	835000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	4089000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	1647000	USD
CY2020Q2	us-gaap	Variable Lease Cost VariableLeaseCost	507000	USD
CY2019Q2	us-gaap	Variable Lease Cost VariableLeaseCost	161000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	734000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	304000	USD
CY2020Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	88000	USD
CY2019Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	88000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	165000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	141000	USD
CY2020Q2	us-gaap	Lease Cost LeaseCost	2565000	USD
CY2019Q2	us-gaap	Lease Cost LeaseCost	1084000	USD
	us-gaap	Lease Cost LeaseCost	4988000	USD
	us-gaap	Lease Cost LeaseCost	2092000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29475000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13693000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4868000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5153000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	25510000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9018000	USD
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	30378000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	14171000	USD
CY2020Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	4180000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2020Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	22031000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2020Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	26211000	USD
CY2019Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	0	USD
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y10M13D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M17D
CY2020Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0677
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0733
CY2020Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P12Y6M
CY2020Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0780
	us-gaap	Operating Lease Payments OperatingLeasePayments	3414000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	1508000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	15000000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	18117000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	11643000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	41212000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3719000	USD
CY2020Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	3000000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6667000	USD
CY2020Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	3000000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6314000	USD
CY2020Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	3000000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5960000	USD
CY2020Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	3000000	USD
CY2020Q2	ptct	Lessee Operating Lease Liability Payments Due Year Fiveand Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter	14844000	USD
CY2020Q2	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	27000000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	37504000	USD
CY2020Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	39000000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7126000	USD
CY2020Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	12789000	USD
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	30378000	USD
CY2020Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	26211000	USD
CY2020Q2	ptct	Investment In Mri InvestmentInMRI	4600000	USD
CY2020Q1	ptct	Payments To Acquire Convertible Debt Investment PaymentsToAcquireConvertibleDebtInvestment	10000000.0	USD
CY2020Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	6.00
	ptct	Debt Instrument Convertible Period DebtInstrumentConvertiblePeriod	P5Y
CY2020Q2	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	2100000	USD
	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	700000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	337021000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3411000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	340430000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	397776000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	787000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	28000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	398535000	USD
CY2020Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	200000	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	200000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	2000	USD
CY2020Q2	us-gaap	Held To Maturity Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	9196000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2020Q2	us-gaap	Held To Maturity Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	0	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	2000	USD
CY2020Q2	us-gaap	Held To Maturity Securities Continuous Unrealized Loss Position Fair Value HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue	9196000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	28000	USD
CY2019Q4	us-gaap	Held To Maturity Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	95990000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2019Q4	us-gaap	Held To Maturity Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	0	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	28000	USD
CY2019Q4	us-gaap	Held To Maturity Securities Continuous Unrealized Loss Position Fair Value HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue	95990000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	255587000	USD
CY2020Q2	ptct	Available For Sale Securities Debt Maturities Over One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue	84843000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	342418000	USD
CY2019Q4	ptct	Available For Sale Securities Debt Maturities Over One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue	56117000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	0	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	0	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-8031000	USD
CY2020Q2	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	0	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-8031000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	568000	USD
	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	568000	USD
CY2020Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	24861000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	38889000	USD
CY2020Q2	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	13452000	USD
CY2019Q4	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	12969000	USD
CY2020Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3295000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3562000	USD
CY2020Q2	ptct	Sales Allowance And Other Related Costs SalesAllowanceAndOtherRelatedCosts	45848000	USD
CY2019Q4	ptct	Sales Allowance And Other Related Costs SalesAllowanceAndOtherRelatedCosts	41155000	USD
CY2020Q2	ptct	Sales Rebates And Royalties Current SalesRebatesAndRoyaltiesCurrent	56870000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-41789000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-294114000	USD
CY2019Q4	ptct	Sales Rebates And Royalties Current SalesRebatesAndRoyaltiesCurrent	42997000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	15465000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10324000	USD
CY2020Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4585000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9380000	USD
CY2020Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	164376000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	159276000	USD
CY2020Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	106309	shares
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	368514	shares
CY2020Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	5400000	USD
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	19000000.0	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-181427000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-113902000	USD
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	65150780	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55912748	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	63769958	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57113141	shares
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.78
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.75
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.61
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.99
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12891606	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11518303	shares
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16910000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10920000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32130000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20184000	USD
CY2020Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	187200000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y29D
	ptct	Debt Instrument Additional Amount Available For Repurchase DebtInstrumentAdditionalAmountAvailableForRepurchase	37500000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q2	ptct	Numberofdistributors Numberofdistributors	2	Number_Distributor
CY2019Q2	ptct	Numberofdistributors Numberofdistributors	2	Number_Distributor
CY2019Q2	ptct	Percentageofnetproductsales Percentageofnetproductsales	0.10
CY2020Q2	ptct	Percentageofnetproductsales Percentageofnetproductsales	0.10
	ptct	Numberofdistributors Numberofdistributors	2	Number_Distributor
	ptct	Numberofdistributors Numberofdistributors	2	Number_Distributor
	ptct	Percentageofnetproductsales Percentageofnetproductsales	0.10
	ptct	Percentageofnetproductsales Percentageofnetproductsales	0.10
CY2020Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7700000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	11700000	USD
CY2020Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2000000.0	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4000000.0	USD
CY2020Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	7700000	USD
CY2019Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	11700000	USD
CY2020Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2019Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2020Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P7Y
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8700000	USD
CY2019Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6600000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16700000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12700000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	17460000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	34920000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	34920000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	34920000	USD
CY2020Q2	ptct	Finite Lived Intangible Assets Amortization Expense Year Five And Thereafter FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter	10094000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	132314000	USD
	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	576500000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	82300000	USD

Files In Submission

Name	View Source	Status
0001070081-20-000128-index-headers.html	Edgar Link	pending
0001070081-20-000128-index.html	Edgar Link	pending
0001070081-20-000128.txt	Edgar Link	pending
0001070081-20-000128-xbrl.zip	Edgar Link	pending
ex101shiratorilicensea.htm	Edgar Link	pending
ex102rpiroyaltypurchas.htm	Edgar Link	pending
ex103kleinemploymentag.htm	Edgar Link	pending
ex104pauwelsemployment.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image011.jpg	Edgar Link	pending
image012.jpg	Edgar Link	pending
image111.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ptct-20200630.htm	Edgar Link	pending
ptct-20200630.xsd	Edgar Link	pending
ptct-20200630_cal.xml	Edgar Link	unprocessable
ptct-20200630_def.xml	Edgar Link	unprocessable
ptct-20200630_htm.xml	Edgar Link	completed
ptct-20200630_lab.xml	Edgar Link	unprocessable
ptct-20200630_pre.xml	Edgar Link	unprocessable
ptct06302020ex-311.htm	Edgar Link	pending
ptct06302020ex-312.htm	Edgar Link	pending
ptct06302020ex-321.htm	Edgar Link	pending
ptct06302020ex-322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTCT
PTC Therapeutics Inc Stock $ptct

2020 Q3 Form 10-Q Financial Statement

#000107008120000128 Filed on August 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT PTC Therapeutics Inc Stock $ptct

2020 Q3 Form 10-Q Financial Statement

#000107008120000128 Filed on August 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT
PTC Therapeutics Inc Stock $ptct